Epoprostenol

Generic Name: Epoprostenol

Brand Names: Flolan, Veletri

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₃₂O_₅

CAS Number: 35121-78-9

Unique Ingredient Identifier: DCR9Z582X0

Background: A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.

Indication: For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

Associated Conditions: Pulmonary Arterial Hypertension (PAH)

Associated Therapies: -

Clinical Trials

PGI2 Versus Nitroglycerine for Management of Pulmonary Hypertension After Valve Surgeries

Phase 1

Conditions: Pulmonary Hypertension

Interventions: Drug: PGI2
Drug: Nitroglycerin

First Posted Date: 2020-10-20

Last Posted Date: 2020-10-20

Lead Sponsor: Ain Shams University

Target Recruit Count: 120

Registration Number: NCT04594629

Locations: 🇪🇬
Ain Shams university, Cairo, Egypt

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

Phase 2

Completed

Conditions: Reperfusion Injury

Interventions: Drug: Sodium chloride solution
Drug: Antithrombin-III
Drug: Infliximab
Drug: Apotransferrin
Drug: Human recombinant erythropoietin
Drug: C1-Inhibitor
Drug: Glutathione
Drug: Alfa-tocopherol
Drug: Melatonin
Drug: Epoprostenol

First Posted Date: 2014-09-26

Last Posted Date: 2024-08-23

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 143

Registration Number: NCT02251041

Locations: 🇧🇪
University Hospitals Leuven, Leuven, Belgium

Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: Nitric Oxide
Drug: Prostacyclin

First Posted Date: 2012-10-30

Last Posted Date: 2017-10-09

Lead Sponsor: Stanford University

Target Recruit Count: 14

Registration Number: NCT01717209

Locations: 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States

Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension

Phase 3

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Epoprostenol

First Posted Date: 2011-11-11

Last Posted Date: 2017-06-26

Lead Sponsor: Actelion

Target Recruit Count: 41

Registration Number: NCT01470144

Locations: 🇨🇦
University of Toronto, Toronoto, Ontario, Canada
🇫🇷
CHU Caen, Caen, France
🇮🇹
Ospedale Sant'Orsola, Bologna, Italy

and more 5 locations

Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: Epoprostenol

First Posted Date: 2011-07-04

Last Posted Date: 2017-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 748

Registration Number: NCT01387191

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: inhaled prostacyclin
Drug: prostacyclin
Drug: subcutaneous and intravenous prostacyclin
Drug: oral ERA
Drug: oral PDE5 inhibitors

First Posted Date: 2010-12-24

Last Posted Date: 2016-02-17

Lead Sponsor: United Therapeutics

Target Recruit Count: 1333

Registration Number: NCT01266265

Locations: 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Northwestern Medical Center, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 85 locations

The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients

Phase 4

Completed

Conditions: Peripheral Microvascular Symptoms
Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Prostaglandin I2

First Posted Date: 2010-02-02

Last Posted Date: 2016-02-15

Lead Sponsor: Yonsei University

Target Recruit Count: 110

Registration Number: NCT01061060

Epoprostenol in Pulmonary Embolism

Phase 4

Completed

Conditions: Acute Pulmonary Embolism

Interventions: Drug: epoprostenol

First Posted Date: 2009-11-16

Last Posted Date: 2009-11-16

Lead Sponsor: Free University Medical Center

Target Recruit Count: 14

Registration Number: NCT01014156

Locations: 🇳🇱
Free University Medical Center, Amsterdam, Netherlands

Prostacyclin's Effect on Platelet Responsiveness

Phase 4

Completed

Conditions: Acute Kidney Failure

Interventions: Drug: prostacyclin
Drug: heparin

First Posted Date: 2009-04-29

Last Posted Date: 2009-04-29

Lead Sponsor: Catholic University of the Sacred Heart

Target Recruit Count: 23

Registration Number: NCT00890214

Locations: 🇮🇹
Policlinico Gemelli, Rome, Italy

PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers

Phase 1

Terminated

Conditions: Headache
Migraine

First Posted Date: 2006-02-14

Last Posted Date: 2006-10-26

Lead Sponsor: Danish Headache Center

Target Recruit Count: 12

Registration Number: NCT00291395

Locations: 🇩🇰
Danish Headache Center, Glostrup, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy